Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor
Although still commonly used in clinical practice to screen and diagnose prostate cancer, there are numerous weaknesses of prostate-specific antigen (PSA) testing, including lack of specificity and the inability to distinguish between aggressive and indolent cancers. A promising prostate cancer biomarker, alpha-methylacyl-CoA racemase (AMACR), has been previously demonstrated to distinguish cancer from healthy and benign prostate cells with high sensitivity and specificity. However, no accurate clinically useful assay has been developed. This study reports the development of a single use, disposable biosensor for AMACR detection. Human blood samples were used to verify its validity, reproducibility and reliability. Plasma samples from 9 healthy males, 10 patients with high grade prostatic intraepithelial neoplasia (HGPIN), and 5 prostate cancer patients were measured for AMACR levels. The average AMACR levels in the prostate cancer patients was 10 fold higher (mean(SD) = 0.077 (0.10)) than either the controls (mean(SD) = 0.005 (0.001)) or HGPIN patients (mean(SD) = 0.004 (0.0005)). At a cutoff of between 0.08 and 0.9, we are able to achieve 100% accuracy in separating prostate cancer patients from controls. Our results provide strong evidence demonstrating that this biosensor can perform as a reliable assay for prostate cancer detection and diagnosis.
References
[1]
Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics. CA Cancer J. Clin.？2010, 60, 277–300, doi:10.3322/caac.20073.
[2]
Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics. CA Cancer J. Clin.？2012, 62, 10–29, doi:10.3322/caac.20138.
[3]
Brawer, M.K.; Chetner, M.P.; Beatie, J.; Buchner, D.M.; Vessella, R.L.; Lange, P.H. Screening for prostatic carcinoma with prostate specific antigen. J. Urol.？1992, 147, 841–845. 1371559
[4]
Catalona, W.J.; Richie, J.P.; Ahmann, F.R.; Hudson, M.A.; Scardino, P.T.; Flanigan, R.C.; de Kernion, J.B.; Ratliff, T.L.; Kavoussi, L.R.; Dalkin, B.L.; et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J. Urol.？1994, 151, 1283–1290. 7512659
[5]
Catalona, W.J.; Smith, D.S.; Ornstein, D.K. Prostate cancer detection in men with serum psa concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free psa measurements. JAMA？1997, 277, 1452–1455, doi:10.1001/jama.1997.03540420048028.
[6]
Cooperberg, M.R.; Lubeck, D.P.; Mehta, S.S.; Carroll, P.R. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from capsure). J. Urol.？2003, 170, S21–S25. discussion S26–S27, doi:10.1097/01.ju.0000095025.03331.c6.
[7]
Di Giuseppe, J.A.; Sauvageot, J.; Epstein, J.I. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am. J. Surg. Pathol.？1997, 21, 174–178, doi:10.1097/00000478-199702000-00006.
[8]
Jemal, A.; Ward, E.; Wu, X.; Martin, H.J.; McLaughlin, C.C.; Thun, M.J. Geographic patterns of prostate cancer mortality and variations in access to medical care in the united states. Cancer Epidemiol. Biomarkers Prev.？2005, 14, 590–595, doi:10.1158/1055-9965.EPI-04-0522.
[9]
Polascik, T.J.; Oesterling, J.E.; Partin, A.W. Prostate specific antigen: A decade of discovery—What we have learned and where we are going. J. Urol.？1999, 162, 293–306, doi:10.1016/S0022-5347(05)68543-6.
[10]
Tosoian, J.; Loeb, S. Psa and beyond: The past, present, and future of investigative biomarkers for prostate cancer. Sci. World J.？2010, 10, 1919–1931, doi:10.1100/tsw.2010.182.
[11]
Draisma, G.; Etzioni, R.; Tsodikov, A.; Mariotto, A.; Wever, E.; Gulati, R.; Feuer, E.; de Koning, H. Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J. Natl. Cancer Inst.？2009, 101, 374–383, doi:10.1093/jnci/djp001.
[12]
Esserman, L.; Shieh, Y.; Thompson, I. Rethinking screening for breast cancer and prostate cancer. JAMA？2009, 302, 1685–1692, doi:10.1001/jama.2009.1498.
[13]
Hakama, M.; Coleman, M.P.; Alexe, D.M.; Auvinen, A. Cancer screening: Evidence and practice in Europe 2008. Eur. J. Cancer？2008, 44, 1404–1413, doi:10.1016/j.ejca.2008.02.013.
[14]
Hasui, Y.; Marutsuka, K.; Asada, Y.; Ide, H.; Nishi, S.; Osada, Y. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate？1994, 25, 91–96, doi:10.1002/pros.2990250206.
[15]
Nadler, R.B.; Humphrey, P.A.; Smith, D.S.; Catalona, W.J.; Ratliff, T.L. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J. Urol.？1995, 154, 407–413, doi:10.1016/S0022-5347(01)67064-2.
[16]
Djavan, B.; Zlotta, A.; Remzi, M.; Ghawidel, K.; Basharkhah, A.; Schulman, C.C.; Marberger, M. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men. J. Urol.？2000, 163, 1144–1148. discussion 1148–1149, doi:10.1016/S0022-5347(05)67711-7.
[17]
Roberts, R.O.; Bergstralh, E.J.; Besse, J.A.; Lieber, M.M.; Jacobsen, S.J. Trends and risk factors for prostate biopsy complications in the pre-psa and psa eras, 1980 to 1997. Urology？2002, 59, 79–84, doi:10.1016/S0090-4295(01)01465-0.
[18]
Wolf, A.M.; Wender, R.C.; Etzioni, R.B.; Thompson, I.M.; D'Amico, A.V.; Volk, R.J.; Brooks, D.D.; Dash, C.; Guessous, I.; Andrews, K.; et al. American cancer society guideline for the early detection of prostate cancer: Update 2010. CA Cancer J. Clin.？2010, 60, 70–98, doi:10.3322/caac.20066.
[19]
Benson, M.C.; Whang, I.S.; Pantuck, A.; Ring, K.; Kaplan, S.A.; Olsson, C.A.; Cooner, W.H. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol.？1992, 147, 815–816. 1371554
[20]
Borofsky, M.S.; Makarov, D.V. Prostate cancer: Psa velocity in prostate cancer screening—The debate continues. Nat. Rev. Urol.？2011, 8, 413–414, doi:10.1038/nrurol.2011.87.
[21]
Oesterling, J.E. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol.？1991, 145, 907–923. 1707989
[22]
Ohori, M.; Dunn, J.K.; Scardino, P.T. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology？1995, 46, 666–671, doi:10.1016/S0090-4295(99)80298-2.
[23]
Essink-Bot, M.L.; de Koning, H.J.; Nijs, H.G.; Kirkels, W.J.; van der Maas, P.J.; Schroder, F.H. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J. Natl. Cancer Inst.？1998, 90, 925–931, doi:10.1093/jnci/90.12.925. 9637143
[24]
Etzioni, R.; Penson, D.F.; Legler, J.M.; di Tommaso, D.; Boer, R.; Gann, P.H.; Feuer, E.J. Overdiagnosis due to prostate-specific antigen screening: Lessons from u.S. Prostate cancer incidence trends. J. Natl. Cancer Inst.？2002, 94, 981–990, doi:10.1093/jnci/94.13.981.
[25]
Fowler, F.J., Jr; Barry, M.J.; Walker-Corkery, B.; Caubet, J.F.; Bates, D.W.; Lee, J.M.; Hauser, A.; McNaughton-Collins, M. The impact of a suspicious prostate biopsy on patients’ psychological, socio-behavioral, and medical care outcomes. J. Gen. Intern. Med.？2006, 21, 715–721, doi:10.1111/j.1525-1497.2006.00464.x.
[26]
Hsieh, C.L.; Oakley-Girvan, I.; Balise, R.R.; Halpern, J.; Gallagher, R.P.; Wu, A.H.; Kolonel, L.N.; O’Brien, L.E.; Lin, I.G.; van Den Berg, D.J.; et al. A genome screen of families with multiple cases of prostate cancer: Evidence of genetic heterogeneity. Am. J. Hum. Genet.？2001, 69, 148–158, doi:10.1086/321281.
[27]
Wiklund, F.; Gillanders, E.M.; Albertus, J.A.; Bergh, A.; Damber, J.E.; Emanuelsson, M.; Freas-Lutz, D.L.; Gildea, D.E.; Goransson, I.; Jones, M.S.; et al. Genome-wide scan of swedish families with hereditary prostate cancer: Suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate？2003, 57, 290–297, doi:10.1002/pros.10303.
Mukherji, M.; Schofield, C.J.; Wierzbicki, A.S.; Jansen, G.A.; Wanders, R.J.; Lloyd, M.D. The chemical biology of branched-chain lipid metabolism. Prog. Lipid Res.？2003, 42, 359–376, doi:10.1016/S0163-7827(03)00016-X.
[30]
Shen, J.; Dudik, L.; Liu, C.-C. An iridium nanoparticles dispersed carbon based thick film electrochemical biosensor and its application for a single use, disposable glucose biosensor. Sens. Actuator. B Chem.？2007, 125, 106–113, doi:10.1016/j.snb.2007.01.043.
[31]
Jiang, Z.; Woda, B.A.; Rock, K.L.; Xu, Y.; Savas, L.; Khan, A.; Pihan, G.; Cai, F.; Babcook, J.S.; Rathanaswami, P.; et al. P504s: A new molecular marker for the detection of prostate carcinoma. Am. J. Surg. Pathol.？2001, 25, 1397–1404, doi:10.1097/00000478-200111000-00007.
